Highly efficient kit yields significant populations of pure myogenic cells

Written by Amsbio
Company news
Cultured skeletal muscle myoblast (iMyoblast) used for isolation studies into Muscular Dystrophies (courtesy: University of Massachusetts)

AMSBIO (Oxford, UK) has introduced an expanded range of Skeletal Muscle Differentiation kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential.  

Using a simple 3-step process of media changes and cell passaging, these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, thereby saving you valuable time.  

Not only do AMSBIO’s Skeletal Muscle Differentiation kits work with all pluripotent stem cell lines, but they also yield a homogeneous and physiologically competent population of cells/cultures immediately suitable for screening and advanced drug discovery.  

AMSBIO can deliver Skeletal Muscle Differentiation kits from stock, as well as offering custom/outsourcing services for generating skeletal muscle myoblasts from your iPSC line of interest, which fits into any workflow, whether you need myoblasts fast or made specifically for your target application. 

For further information please visit here or contact AMSBIO directly.

About AMSBIO
AMSBIO, part of the Europa Biosite group, is a leading life sciences company supporting drug discovery, translational research and cell and gene therapy across Europe, North America and wider international markets. With in depth expertise in advanced cell culture, 3D cell models and cryopreservation, AMSBIO is well placed to help researchers progress from early discovery through to clinical and GMP-ready applications. The company’s portfolio of innovative products and services supports multiple stages of the research pipeline, spanning target discovery, assay development and disease modeling, through to stem cell and organoid-based research. Key solutions include the integrated stem cell platform combining StemFit™ media, iMatrix™ recombinant laminins and CELLBANKER™ cryopreservation technology, alongside extracellular matrix technologies, biospecimens, glycobiology tools, kits and assays, and a wide range of custom services, including viral delivery. Drawing on extensive GMP expertise and a comprehensive human and animal biorepository, AMSBIO is internationally recognized for delivering high-quality, application-ready products and services. AMSBIO has a consistent record of close scientific collaboration with partners in academic, biotech and pharmaceutical markets to translate innovation from bench to bedside. 

  You might also be interested in...